University of Warwick

Firmly established as one of the UK’s top universities, the University of Warwick is renowned for being forward-looking and ambitious, with an acknowledged reputation for excellence in research and teaching.

Still a relatively young institution – established in 1965 – from the outset Warwick quickly became known for our entrepreneurialism and for building strong links with business and industry. Our reputation for employability, academic excellence and a desire to do things differently is reflected in our consistently high performance in Higher Education league tables. We are ranked 3rd most targeted university by UK’s top 100 employers (The Graduate Market in 2020, High Fliers Research), 8th in Europe for teaching and learning environment (Times Higher Education 2019), and 20th Most International University in the World (Times Higher Education 2021).

As a leading UK research institution, we are committed to research that is internationally recognised and impactful. Our researchers are inspired by fundamental questions led by our intellectual curiosity. They are supported to deliver provocative, interdisciplinary research which aims to create knowledge and transform the way we understand the world.

Warwick’s expertise currently spans 31 academic departments and more than 50 research centres and institutes across three Faculties: Arts; Science, Engineering and Medicine; and Social Sciences. Our Global Research Priorities are helping to improve the lives of people around the world by bringing our research teams from many different disciplines in order to tackle some of the most complex global challenges.

Learn more

    University of Warwick News

    Nordic Biotech: the search for the holes in the market

    News Editor Thomas Lau spoke to Florian Schönharting, a partner at the Nordic Biotech, a fund that has invested in Denmark’s Gastrotech BipPharma - a biotechnology company that recently merged with US biotech firm DOR BioPharma. Nordic Biotech, a specialised biotech venture capital fund focusing primarily on Nordic countries and the EU, has invested in Gastrotech since its inception in March 2003.
    04 Jan 2006
    News

    Austrian Intercell affiliate aims to cut hospital infections

    At any given time over 1.4 million people worldwide are suffering from infections they got from their health-provider, according to the World Health Organization. Pelias AG, a newly created affiliate of Austrian biotech company Intercell AG, is hoping to raise €15 million to €20 million to make a dent in those numbers.
    04 Jan 2006
    News

    India bullish on global clinical trial business opportunity

    Time and money are driving the world’s pharmaceutical companies east for their clinical trials. With its huge population, new helpful regulations and growth outstripping China, India plans to become the world leader in the clinical research business by the end of the decade.
    04 Jan 2006
    News

    Sworn enemies unite against draft EU IP law

    Sworn enemies within the technology and pharmaceutical industries are joining forces in a lobbying drive to persuade European Union lawmakers to change a draft law they say will stifle innovation in Europe by criminalising patent infringements, along with all forms of intellectual property infringements.
    04 Jan 2006
    News

    Sigma-Aldrich goes shopping

    Lab-supply companies are normally in the business of selling things to scientists, rather than buying. But the new CEO of Sigma-Aldrich, one of the world's largest lab-supply firms, is shopping for new ideas, new partners - and new companies to invest in.
    04 Jan 2006
    News